News about Global Pharma

Lightpoint Performs World's First Bladder Cancer SLN Procedure with SENSEI

Lightpoint Surgical Ltd., an affiliate of Telix Pharmaceuticals Ltd. has achieved a new milestone with world’s first bladder cancer sentinel lymph node (SLN) procedure with SENSEI

Global Pharma | 27/03/2024 | By Manvi |  583

INOVIO Plans to Participate in The Novel Therapeutics Forum at Penn Medicine

INOVIO has announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine

Global Pharma | 27/03/2024 | By Manvi |  647

Sanofi and Cipla Partner to Expand CNS Portfolio Distribution in India

As part of the partnership, Cipla will take on the responsibility of distributing Sanofi India's six CNS brands, including Frisium®, a notable name in the anti-epileptic medication category.

Global Pharma | 27/03/2024 | By Abha |  651

Bridge Biotherapeutics New Venture into Immuno-Oncology with University of Colorado

Bridge Biotherapeutics has forged a research collaboration with Dr. Raul Torres's Lab at the University of Colorado School of Medicine.

Global Pharma | 27/03/2024 | By Manvi |  511

AstraZeneca Pharma India Names Vinay Sharma as Business Unit Head for Rare Disease Unit

Sharma is a Post?Graduate in Marketing Management and Business Administration with over 23 years of industry experience.

Global Pharma | 27/03/2024 | By Abha |  929

STEMCELL Announces FDA De Novo Classification for Its EasySep CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

STEMCELL Technologies announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.

Global Pharma | 26/03/2024 | By Manvi |  383

Andelyn Biosciences Partners with Grace Science to Accelerate Development of NGLY1 Gene Therapy

NGLY1 Deficiency is a severe, life-threatening condition characterized by developmental delay, cognitive impairment, movement disorders, and other debilitating neurological symptoms.

Global Pharma | 26/03/2024 | By Abha |  648

Novo Nordisk to Acquire Cardior Pharmaceuticals for up to EUR 1.025 Billion

At the heart of the acquisition is Cardior's lead compound, CDR132L, currently in phase 2 clinical development for the treatment of heart failure.

Global Pharma | 26/03/2024 | By Abha |  345

Poseida Therapeutics Welcomes Syed Rizvi as New Chief Medical Officer

Poseida Therapeutics, Inc. has appointed Syed Rizvi, MD, as Chief Medical Officer effective April 1, 2024.
<br />

Global Pharma | 26/03/2024 | By Manvi |  923

Scivita Medical Signs Extended Partnership with Boston Scientific

Scivita Medical Technology Co., Ltd. has signed an expanded strategic cooperation arrangement with Boston Scientific.

Global Pharma | 26/03/2024 | By Manvi |  568